soul trial oral semaglutide cardiovascular outcomes 2024 results nejm π§Ώ is the first oral GLP-1 RA proven to reduce MACE in high-risk T2DM patients, extending protection beyond injectable formulations. Trial: Oral Semaglutide & Cardiovascular in T2DM SELECT Trial
Pay in 4 interest-free payments of $5.08 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 15 - Aug 20






























